13F-HR filed by TCG Crossover Management, LLC
TCG Crossover Management, LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 29 holding rows worth $901,701,904.
- Accession
- 0001214659-24-002612
- Filer
- CIK 1839948
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 29 entries on the cover page, a total value of $901,701,904 stated on the cover page (in dollars after the unit check, H1), rows summing to $901,701,904 with VALUE read as dollars as filed, 13F file number 028-22283. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 2,109,584 | $85,986,644 | dollars as filed | |
| INHIBRX INC | 45720L107 | COM | 1,750,387 | $66,514,706 | dollars as filed | |
| ICOSAVAX INC | 45114M109 | COM | 3,703,704 | $58,370,375 | dollars as filed | |
| AN2 THERAPEUTICS INC | 037326105 | COM | 2,678,209 | $54,876,502 | dollars as filed | |
| RAYZEBIO INC | 75525N107 | COM | 869,908 | $54,082,180 | dollars as filed | |
| AEROVATE THERAPEUTICS INC | 008064107 | COM | 2,201,274 | $49,814,831 | dollars as filed | |
| GERON CORP | 374163103 | COM | 23,375,839 | $49,323,020 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 10,000,000 | $47,000,000 | dollars as filed | |
| GRACELL BIOTECHNOLOGIES INC | 38406L103 | ADR | 4,514,786 | $45,328,451 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 179,917 | $41,629,195 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 3,395,495 | $41,594,814 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 2,104,875 | $36,561,679 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 3,858,000 | $33,757,500 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 5,631,042 | $33,110,527 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 1,989,103 | $27,549,077 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 1,007,902 | $26,386,874 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 1,142,857 | $23,142,854 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 1,650,150 | $21,946,995 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 1,423,642 | $20,471,972 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 2,040,816 | $16,244,895 | dollars as filed | |
| VISTAGEN THERAPEUTICS INC | 92840H202 | COM | 2,676,580 | $13,757,621 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 1,100,000 | $11,770,000 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 486,795 | $11,050,247 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 584,955 | $8,826,971 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 717,654 | $7,406,189 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 1,276,574 | $7,212,643 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 2,912,861 | $5,155,764 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 815,724 | $2,014,838 | dollars as filed | |
| KODIAK SCIENCES INC | 50015M109 | COM | 267,941 | $814,540 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-24-002612 | this filing | 2024-02-14 | acceptance time not in the bulk data set |